Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study

Abstract

Objectives Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been affecting many people on earth and our society. Japan is known to have relatively smaller number of its infections as well as deaths among developed nations. However, accurate prevalence of COVID-19 in Japan remains unknown. Therefore, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection. Methods We conducted a cross-sectional serologic testing for SARS-CoV-2 antibody using 1000 samples from patients at outpatient settings who visited the clinic from March 31 to April 7, 2020, stratified by the decade of age and sex. Results There were 33 positive IgG among 1000 serum samples (3.3%, 95%CI: 2.3–4.6%). By applying this figure to the census of Kobe City (population: 1,518,870), it is estimated that the number of people with positive IgG be 50,123 (95%CI: 34,934–69,868). Age and sex adjusted prevalence of positivity was calculated 2.7% (95%CI: 1.8–3.9%), and the estimated number of people with positive IgG was 40,999 (95%CI: 27,333–59,221). These numbers were 396 to 858-fold more than confirmed cases with PCR testing in Kobe City. Conclusions Our cross-sectional serological study suggests that the number of people with seropositive for SARS-CoV-2 infection in Kobe, Japan is far more than the confirmed cases by PCR testing.

Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers

“…Since the emergence of SARS-CoV-2, assessing and understanding the kinetics and protective role of the human immune response against this virus, has been of a high priority and relevance [ 4 ]. For this purpose, different investigations have conducted several seroepidemiological surveys worldwide to measure the seroprevalence of antibodies against SARS-CoV-2 [ 5 , 6 , 7 , 8 , 9 , 10 , 11 ]. These studies have demonstrated the importance of the humoral immune response for the elimination of viral infection, and the important role of understanding the dynamics of antibodies against SARS-CoV-2, which help not only in assessing immunological levels and predicting potential immune protection, but also in the development of vaccine and immune therapy strategies [ 12 ].…”

Sero-prevalence of anti-SARS-CoV-2 antibodies among healthcare workers: A multicenter study from Egypt

“…Positive detection of SARS-CoV-2 RNA in nasopharyngeal swab samples, sputum samples or bronchoalveolar lavage samples by reverse transcriptase polymerase chain reaction (RT–PCR) has been used to confirm SARS-CoV-2 infection. Recently, positive detection of IgM and IgG antibodies specific to SARS-CoV-2 has also been recognized as deterministic evidence for confirmed SARS-CoV-2 infection [ 4 , 5 ].…”

Comparison of the Prevalence of Antibodies to SARS-CoV-2 in 9954 Recruits in the Korean Army Training Center with the General Korean Population of Equivalent Age Between September and November, 2020

“…In a study of dialysis patients in the United States, 8~9% of the population was estimated to be infected, but less than 2% were confirmed cases [ 14 ]. In a cross-sectional study of outpatients in Kobe, Japan, seroprevalence was 396 to 858 times higher than the number of confirmed cases [ 15 ].…”

“…Moreover, despite high urbanization and population density, there were relatively few missed cases. Kobe, Japan had an estimated seroprevalence of 2.7%, while Santa Clara County had 1.2% [ 13 , 15 ]. However, highly urbanized New York state showed an average of 12.5% positives, and numbers increased in densely populated areas such as New York City, with 20.2% [ 17 ].…”